RU2013132683A - Ингибиторы репликации вирусов гриппа - Google Patents
Ингибиторы репликации вирусов гриппа Download PDFInfo
- Publication number
- RU2013132683A RU2013132683A RU2013132683/04A RU2013132683A RU2013132683A RU 2013132683 A RU2013132683 A RU 2013132683A RU 2013132683/04 A RU2013132683/04 A RU 2013132683/04A RU 2013132683 A RU2013132683 A RU 2013132683A RU 2013132683 A RU2013132683 A RU 2013132683A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- independently
- optionally substituted
- optionally
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 42
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 13
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 238000004177 carbon cycle Methods 0.000 claims abstract 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims abstract 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 3
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims 39
- -1 cyano, hydroxy Chemical group 0.000 claims 31
- 125000004043 oxo group Chemical group O=* 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 0 Cc1c(*)cnc(C)n1 Chemical compound Cc1c(*)cnc(C)n1 0.000 description 14
- BHFSMDPSSVQLOD-UHFFFAOYSA-N Cc(c(C#N)c1)nc(C)c1F Chemical compound Cc(c(C#N)c1)nc(C)c1F BHFSMDPSSVQLOD-UHFFFAOYSA-N 0.000 description 2
- HEMCGZPSGYRIOL-UHFFFAOYSA-N C(C1)C11CCCC1 Chemical compound C(C1)C11CCCC1 HEMCGZPSGYRIOL-UHFFFAOYSA-N 0.000 description 1
- GJJWOCIFFXEBPU-UHFFFAOYSA-N CC(C(CC12)CN=C1NCC2C1NC(NC2CCCCC2)NCC1(C)N)(F)F Chemical compound CC(C(CC12)CN=C1NCC2C1NC(NC2CCCCC2)NCC1(C)N)(F)F GJJWOCIFFXEBPU-UHFFFAOYSA-N 0.000 description 1
- CUMNGZMHERFBAQ-HMNKSOQGSA-N CCC(C(C1)[C@@H](C)NC=C1C(F)(F)F)c1nc(NC(CCCC2)[C@H]2C(O)=O)ncc1N Chemical compound CCC(C(C1)[C@@H](C)NC=C1C(F)(F)F)c1nc(NC(CCCC2)[C@H]2C(O)=O)ncc1N CUMNGZMHERFBAQ-HMNKSOQGSA-N 0.000 description 1
- PIIRZLZCOKFAAZ-MCZRRMNISA-N COC([C@@H](C1CCC2CC1)[C@H]2Nc1cc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O Chemical compound COC([C@@H](C1CCC2CC1)[C@H]2Nc1cc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O PIIRZLZCOKFAAZ-MCZRRMNISA-N 0.000 description 1
- QMCMZEDXEDPDTP-AMDVSUOASA-N COC([C@H]1C(CC2)CCC2C1)=O Chemical compound COC([C@H]1C(CC2)CCC2C1)=O QMCMZEDXEDPDTP-AMDVSUOASA-N 0.000 description 1
- YJXZVXMYASVALG-DRSMGJIXSA-N CO[IH]([C@@H](C1CCC2CC1)[C@H]2Nc(cc(-c1c[nH]c(nc2)c1cc2F)c(C#N)c1)c1F)=O Chemical compound CO[IH]([C@@H](C1CCC2CC1)[C@H]2Nc(cc(-c1c[nH]c(nc2)c1cc2F)c(C#N)c1)c1F)=O YJXZVXMYASVALG-DRSMGJIXSA-N 0.000 description 1
- VWUNZXFNDJUNMT-CCOGEBNFSA-N C[C@@H](C1CCC2CC1)C2Nc(nc1)nc(-c(c2c3)c[nH]c2ncc3F)c1F Chemical compound C[C@@H](C1CCC2CC1)C2Nc(nc1)nc(-c(c2c3)c[nH]c2ncc3F)c1F VWUNZXFNDJUNMT-CCOGEBNFSA-N 0.000 description 1
- LGODIPGSIRJWMT-UHFFFAOYSA-N Cc(c(F)c1)nc(C)c1F Chemical compound Cc(c(F)c1)nc(C)c1F LGODIPGSIRJWMT-UHFFFAOYSA-N 0.000 description 1
- SSYHSUNUQGJTDK-UHFFFAOYSA-N Cc(nc1C)ccc1F Chemical compound Cc(nc1C)ccc1F SSYHSUNUQGJTDK-UHFFFAOYSA-N 0.000 description 1
- VXROUMWEJBCDBZ-UHFFFAOYSA-N Cc1nc(C)cc(C(F)(F)F)c1 Chemical compound Cc1nc(C)cc(C(F)(F)F)c1 VXROUMWEJBCDBZ-UHFFFAOYSA-N 0.000 description 1
- VFMCCTVTAZJFQA-AKPINYAASA-N OC([C@@H](C1CCC2CC1)[C@H]2Nc1cc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O Chemical compound OC([C@@H](C1CCC2CC1)[C@H]2Nc1cc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O VFMCCTVTAZJFQA-AKPINYAASA-N 0.000 description 1
- IQJOXHUMARIQTH-QPGDOINGSA-N OC([C@H](C1CCC2CC1)[C@@H]2Nc(nc1)nc(-c2c[nH]c(nc3)c2cc3F)c1F)=O Chemical compound OC([C@H](C1CCC2CC1)[C@@H]2Nc(nc1)nc(-c2c[nH]c(nc3)c2cc3F)c1F)=O IQJOXHUMARIQTH-QPGDOINGSA-N 0.000 description 1
- VFMCCTVTAZJFQA-PEOAOIFPSA-N OC([C@H](C1CCC2CC1)[C@@H]2Nc1cc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O Chemical compound OC([C@H](C1CCC2CC1)[C@@H]2Nc1cc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O VFMCCTVTAZJFQA-PEOAOIFPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42393310P | 2010-12-16 | 2010-12-16 | |
| US61/423,933 | 2010-12-16 | ||
| US201161527277P | 2011-08-25 | 2011-08-25 | |
| US61/527,277 | 2011-08-25 | ||
| PCT/US2011/065389 WO2012083122A1 (en) | 2010-12-16 | 2011-12-16 | Inhibitors of influenza viruses replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013132683A true RU2013132683A (ru) | 2015-01-27 |
Family
ID=45464909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013132683/04A RU2013132683A (ru) | 2010-12-16 | 2011-12-16 | Ингибиторы репликации вирусов гриппа |
Country Status (10)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| RU2013132681A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| PT3068776T (pt) | 2013-11-13 | 2019-08-26 | Vertex Pharma | Inibidores da replicação de vírus da gripe |
| HUE038820T2 (hu) | 2013-11-13 | 2018-11-28 | Vertex Pharma | Eljárás influenzavírusok replikációjának inhibitorai elõállítására |
| RU2016129380A (ru) | 2013-12-20 | 2018-01-25 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием |
| EA201790266A1 (ru) * | 2014-08-08 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Индолы для применения при инфекции, вызванной вирусом гриппа |
| SG11201701621YA (en) | 2014-09-08 | 2017-03-30 | Janssen Sciences Ireland Uc | Pyrrolopyrimidines for use in influenza virus infection |
| EP3929293A3 (en) | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| ES2882671T3 (es) * | 2015-11-27 | 2021-12-02 | Janssen Sciences Ireland Unlimited Co | Indoles heterocíclicos para su uso en infecciones por el virus de la gripe |
| EP3362451B1 (en) | 2015-12-09 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| BR112018014794A2 (pt) * | 2016-01-20 | 2018-12-11 | Janssen Sciences Ireland Uc | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| WO2017133664A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza |
| WO2017133667A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof |
| WO2017133658A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2017133657A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2017133665A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | 6,7-diazaindazole and 6,7-diazaindole derivatives and use in treatment, amelioration or prevention of influenza thereof |
| CN107759571B (zh) | 2016-08-16 | 2021-03-02 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| US10647693B2 (en) * | 2016-08-30 | 2020-05-12 | North & South Brother Pharmacy Investment Company Limited | Inhibitors of influenza virus replication, application methods and uses thereof |
| CA3045371C (en) | 2016-12-15 | 2024-05-14 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| US10927118B2 (en) | 2017-03-02 | 2021-02-23 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CN108727369B (zh) * | 2017-04-25 | 2023-06-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| WO2018237245A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS |
| TWI821343B (zh) * | 2018-07-27 | 2023-11-11 | 美商共結晶製藥公司 | 流感病毒複製之抑制劑 |
| BR112021002440A2 (pt) | 2018-08-10 | 2021-05-04 | University Of Massachusetts | oligonucleotídeos modificados visando snps |
| WO2020041769A1 (en) | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CN109678738B (zh) * | 2018-12-26 | 2021-11-30 | 深圳市华先医药科技有限公司 | 一种合成(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| EP3946369A4 (en) | 2019-03-26 | 2023-10-18 | University Of Massachusetts | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| AU2021244600A1 (en) | 2020-03-26 | 2022-11-03 | University Of Massachusetts | Synthesis of modified oligonucleotides with increased stability |
| IL297069A (en) * | 2020-04-10 | 2022-12-01 | Cocrystal Pharma Inc | Replication inhibitors of norovirus and corona virus |
| CA3174079A1 (en) | 2020-05-26 | 2021-12-02 | Anastasia Khvorova | Synthetic oligonucleotides having regions of block and cluster modifications |
| CN112063726A (zh) * | 2020-09-21 | 2020-12-11 | 杭州市疾病预防控制中心 | 一种用于检测奥司他韦耐药突变的引物、探针及检测方法 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004509897A (ja) | 2000-09-22 | 2004-04-02 | イーライ・リリー・アンド・カンパニー | シクロヘキシルアミン誘導体の立体選択的製造方法 |
| CA2456292A1 (en) | 2001-08-14 | 2003-02-27 | Toyama Chemical Co., Ltd. | Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog |
| TWI339206B (en) * | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| UA87494C2 (en) * | 2004-03-30 | 2009-07-27 | Вертекс Фармасьютикалс Инкорпорейтед | Azaindoles useful as inhibitors of jak and other protein kinases |
| ES2364340T3 (es) * | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| US20060161001A1 (en) * | 2004-12-20 | 2006-07-20 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| AU2006247322A1 (en) * | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
| CN101801971A (zh) * | 2005-09-30 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的脱氮嘌呤 |
| NZ592968A (en) | 2006-01-17 | 2012-08-31 | Vertex Pharma | Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2 |
| WO2008079346A1 (en) * | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| US8173635B2 (en) | 2007-11-02 | 2012-05-08 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| NZ590784A (en) | 2008-07-23 | 2012-12-21 | Vertex Pharma | Pyrazolopyridine kinase inhibitors |
| CA2731432A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| MX2011000837A (es) | 2008-07-23 | 2011-04-05 | Vertex Pharma | Inhibidores de pirazolpiridina cinasa triciclica. |
| US20100038988A1 (en) | 2008-08-12 | 2010-02-18 | Gannon Ramy | Stator and Method of Making the Same |
| GEP20207129B (en) * | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| US8435980B2 (en) * | 2009-07-15 | 2013-05-07 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
-
2011
- 2011-12-16 AU AU2011343647A patent/AU2011343647A1/en not_active Abandoned
- 2011-12-16 RU RU2013132683/04A patent/RU2013132683A/ru not_active Application Discontinuation
- 2011-12-16 CN CN201180066551.2A patent/CN103562205A/zh active Pending
- 2011-12-16 EP EP11806096.1A patent/EP2651938A1/en not_active Withdrawn
- 2011-12-16 CA CA2822062A patent/CA2822062A1/en not_active Abandoned
- 2011-12-16 KR KR1020137018522A patent/KR20130128435A/ko not_active Withdrawn
- 2011-12-16 MX MX2013006840A patent/MX2013006840A/es not_active Application Discontinuation
- 2011-12-16 JP JP2013544810A patent/JP2013545818A/ja active Pending
- 2011-12-16 WO PCT/US2011/065389 patent/WO2012083122A1/en not_active Ceased
-
2013
- 2013-06-14 US US13/918,115 patent/US20130345218A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011343647A1 (en) | 2013-05-02 |
| CN103562205A (zh) | 2014-02-05 |
| KR20130128435A (ko) | 2013-11-26 |
| MX2013006840A (es) | 2014-01-31 |
| CA2822062A1 (en) | 2012-06-21 |
| JP2013545818A (ja) | 2013-12-26 |
| WO2012083122A1 (en) | 2012-06-21 |
| US20130345218A1 (en) | 2013-12-26 |
| WO2012083122A8 (en) | 2013-12-05 |
| EP2651938A1 (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013132717A (ru) | Ингибиторы репликации вирусов гриппа | |
| RU2013132681A (ru) | Ингибиторы репликации вирусов гриппа | |
| JP2013545817A5 (cg-RX-API-DMAC10.html) | ||
| JP2013545818A5 (cg-RX-API-DMAC10.html) | ||
| JP2013545816A5 (cg-RX-API-DMAC10.html) | ||
| JP2012522729A5 (cg-RX-API-DMAC10.html) | ||
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| RU2014122340A (ru) | Ингибиторы вируса гепатита с, имеющие жесткую вытянутую цепь и содержащие фрагмент {2-[4-(бифенил-4-ил)-1н-имидазо-2-ил]пирролидин-1-карбонилметил}амина | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| RU2016151727A (ru) | Нейроактивные стероиды, композиции и их применения | |
| AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
| JP2023553835A5 (cg-RX-API-DMAC10.html) | ||
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR061761A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
| RU2015143990A (ru) | Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана | |
| JP2017511815A5 (cg-RX-API-DMAC10.html) | ||
| RU2018124984A (ru) | Контрастные агенты | |
| BR112015003778B1 (pt) | Profármaco de tenofovir, composição farmacêutica, e seus usos | |
| AR087418A1 (es) | Inhibidores de replica de virus de influenza | |
| AR066171A1 (es) | Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. | |
| RU2009124304A (ru) | Производные азабициклооктана, способ их получения и их применения в качестве ингибиторов дипептидилпептидазы iv | |
| RU2014113539A (ru) | Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20141217 |